AI Summary
Summary: This study examines the relationship between tumor mutational burden (TMB) status in patients with metastatic castration-resistant prostate cancer and their response to immune checkpoint inhibitor therapy. The study is a single-center cohort study.
This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.